Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

Impact · against what's priced in

The presentation of CLASP II TR and PROGRESS trial results provides positive visibility for Edwards Lifesciences' Tricuspid and TAVR pipelines. While trial data updates are generally catalysts, the impact is limited to incremental visibility until specific clinical outcomes are quantified.

EW+0.20: No priced-in read yet

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

How each ticker is affected

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

How each ticker is affected

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

Track these names every morning.

Fresenius Medical cuts top end of 2026 profit outlook

ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

Wall Street Analysts Think Globus Medical (GMED) Could Surge 30.52%: Read This Before Placing a Bet

Tiziana's experimental MS treatment meets main goals in mid-stage study

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

How each ticker is affected

Next reads from the same story arc

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript

How each ticker is affected

Next reads from the same story arc

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

Track these names every morning.

Fresenius Medical cuts top end of 2026 profit outlook

ONWARD Medical Delivers Revenue of EUR 2.5M in Q3 2026, with Sustained Commercial Momentum and Strong Clinical Execution

Wall Street Analysts Think Globus Medical (GMED) Could Surge 30.52%: Read This Before Placing a Bet

Tiziana's experimental MS treatment meets main goals in mid-stage study